Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.39B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.18M
Average 0.08M
Returns on capital
Nanobiotix S.A. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
28.4%
avg 403.0%
ROIC
-74.3%
avg -122.8%
ROA
-35.4%
avg -62.1%
Analysis
ROE is currently the strongest return metric at 28.4% versus its period average of 403.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | EUR 949.24K | 53 | — | — |
Louis Kayitalire | Chief Medical Officer & Member of Executive Board | EUR 677.64K | 67 | — | — |
Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | EUR 675.62K | 52 | — | — |
Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | EUR 465.59K | 52 | — | — |
Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | — | — | — | — |
Arnd Christ | CFO & Member of Executive Board | — | 60 | — | — |
Margaret Galluzzi | Vice President & Global Head of Clinical Operations | — | — | — | — |
Brandon Owens | Vice President of Strategic Marketing & Corporate Communication | — | — | — | — |
Earl J. Bergey | Co-Founder | — | 71 | — | — |
Anne-Sophie Lariviere | Chief Product Innovation & Delivery Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +83.8% | +37.6% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +83.8% over three years. Forward estimates point to Revenue at +37.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Nanobiotix S.A. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NBTX's management, answered from reported figures.
Who manages NBTX?
Nanobiotix S.A. (NBTX) lists 10 active executives. The top listed executive is Laurent Levy, Co-Founder, President of the Executive Board & Chief Executive Officer.
Continue the stock analysis
Jump to another research area for this company.